In vivo, our KIF18A inhibitors showed significant PD and anti-cancer effects in multiple TP53-mutant CIN+ tumor models but had no anti-cancer effect on the TP53-WT CIN− tumor model. This evidence concerns the gene TP53 and neoplasm.